Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With cOlorectal Cancer Treated With AvaStin Based First Line Regimens (CRONOS 1)

Trial Profile

The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With cOlorectal Cancer Treated With AvaStin Based First Line Regimens (CRONOS 1)

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CRONOS 1
  • Sponsors Roche

Most Recent Events

  • 14 Sep 2016 Status changed from active, no longer recruiting to discontinued as contract terminated with Site Management Organization.
  • 05 Feb 2015 Planned End Date changed from 1 Jun 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.
  • 05 Feb 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top